Division of Medical Oncology, Duke University Health System, Durham, North Carolina, USA.
Division of Hematologic Malignancies & Cellular Therapy, Duke University Health System, Durham, North Carolina, USA.
BMJ Case Rep. 2023 May 17;16(5):e252739. doi: 10.1136/bcr-2022-252739.
The tyrosine kinase inhibitor dasatinib is approved for the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL). Patients on dasatinib can rarely develop a form of benign reversible reactive lymphadenopathy termed follicular lymphoid hyperplasia (FLH). Here, we describe a patient with Ph+ ALL who developed follicular lymphoma (FL) after prolonged treatment with dasatinib and who had complete remission of FL after discontinuation of dasatinib. This case suggests that dasatinib-associated FLH could be a premalignant condition that can transform into FL. Moreover, withdrawal of dasatinib may be sufficient for remission of dasatinib-associated FL.
酪氨酸激酶抑制剂达沙替尼获批用于治疗慢性髓性白血病和费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）。接受达沙替尼治疗的患者罕见地会发生一种良性可逆反应性淋巴结病，称为滤泡性淋巴组织增生（FLH）。在这里，我们描述了一例 Ph+ ALL 患者，在接受达沙替尼长期治疗后发展为滤泡性淋巴瘤（FL），在停用达沙替尼后 FL 完全缓解。该病例提示达沙替尼相关的 FLH 可能是一种癌前状态，可转化为 FL。此外，停用达沙替尼可能足以缓解达沙替尼相关的 FL。
